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Abstract
Introduction Hereditary angioedema (HAE) is a rare
disorder characterized by C1 esterase inhibitor (C1-INH)
deficiency, resulting in periodic attacks of acute edema that
can be life-threatening if they occur in the laryngeal region.
We assessed the efficacy of C1-INH concentrate in the
emergency treatment of rarely occurring acute laryngeal
HAE attacks in a prospective, open-label clinical study.
Methods Acute laryngeal attacks were each treated with
C1-INH concentrate (Berinert) at a single dose of 20 U/kg
body weight. Efficacy endpoints included time to onset of
symptom relief and time to complete resolution of all
symptoms, each based on the patient's assessment.
Results All 39 laryngeal attacks in 16 patients were treated
successfully. The median time to onset of symptom relief
was 15 min. The median time to complete resolution of all
symptoms was 8.25 h. No treatment-related serious adverse
events occurred, and the treatment was well tolerated. The
administration of C1-INH concentrate was not associated
with any viral infections.
Conclusion C1-INH concentrate is an effective and safe
emergency treatment for providing reliable and rapid relief
from the potentially life-threatening symptoms of laryngeal
HAE attacks.
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Introduction
Hereditary angioedema (HAE) is a rare disease in which an
inherited functional deficiency of C1 esterase inhibitor (C1-
INH) is clinically characterized by unpredictable episodes
of edema at various body locations [1, 2]. C1-INH is an
important control protein of the complement and kallikrein–
kinin cascade systems [3]. During HAE attacks, these
plasma proteolytic cascades are activated and, due to either
t h ec o m p l e t el a c ko fC 1 - I N H( t y p eIH A E )o rt h e
expression of dysfunctional C1-INH (type II HAE), result
in enhanced vascular permeability, leading to local subcu-
taneous or submucous swellings. The most frequent
symptoms of HAE are acute episodes of skin swellings or
abdominal pain that can be inconvenient and painful but
which are not life-threatening. In contrast, the rare
(approximately 1% of HAE attacks [4]) but potentially
life-threatening episodes of laryngeal edema are associated
with a risk of asphyxiation, which is the most important
symptom of concern for patients with HAE [5]. Clinical
manifestations of laryngeal attacks include hoarseness,
stridor, dyspnea, the feeling of having a lump in the larynx,
dysphagia, and voice change [4, 6].
The first-line therapy for acute HAE attacks is replace-
ment therapy with C1-INH concentrate as recommended in
the 2007 International Consensus Algorithm for the
Management of HAE [7]. Before the availability of
effective treatments, up to 25% to 30% of patients with
HAE died from laryngeal edema [8]. An even higher
mortality of approximately 50% has been reported for
patients with undiagnosed HAE [9]. Since the introduction
of C1-INH concentrate in several countries, the rate of
mortality has decreased dramatically, but patients with HAE
still die from laryngeal attacks that are not treated with C1-
INH concentrate [10, 11]. Due to the danger of asphyxia-
tion, it is vital that acute attacks of laryngeal edema are
treated effectively before reaching their maximum devel-
opment. During this time, emergency intervention proce-
dures include the administration of C1-INH concentrate, the
administration of oxygen, intubation, and tracheotomy [5].
The efficacy and safety of C1-INH concentrate have
been demonstrated in clinical use for more than 30 years,
involving over 400,000 treatments in patients with HAE;
this evidence is based mainly upon the treatment of acute
abdominal and facial attacks using a fixed dose of C1-INH
concentrate [2, 12–15]. Information on the efficacy of C1-
INH concentrate in the emergency treatment of laryngeal
edema is limited [16].
Here, we report on data obtained from 39 laryngeal
attacks in 16 patients with HAE that were treated with C1-
INH concentrate (Berinert; CSL Behring, Marburg,
Germany) in a prospective, open-label clinical study
(International Multicenter Prospective Angioedema, C1-
INH Trial 2 [I.M.P.A.C.T.2]). This highly purified C1-INH
concentrate is produced from human plasma obtained in the
USA. It is rendered free of detectable virus by two
independent steps of virus inactivation and removal [17].
The I.M.P.A.C.T.2 study is an extension of the placebo-
controlled I.M.P.A.C.T.1 study that had previously estab-
lished 20 U/kg as an effective dose of C1-INH concentrate
in the treatment of acute HAE attacks [15]. While only
single abdominal and facial HAE attacks were treated in I.
M.P.A.C.T.1, repeated attacks in all body locations were
treated in I.M.P.A.C.T.2. Here, we analyze the treatment of
the laryngeal attacks that occurred in I.M.P.A.C.T.2. Our
focus is to evaluate whether C1-INH concentrate given at
the weight-based dose of 20 U/kg, which had demonstrated
efficacy compared to placebo against abdominal and facial
attacks in I.M.P.A.C.T.1, is also as effective at providing
rapid relief from the symptoms of laryngeal edema. Due to
the life-threatening nature of laryngeal attacks and the
evidence from retrospective reports for the efficacy of C1-
INH concentrate in the treatment of laryngeal attacks, a
placebo-controlled investigation of laryngeal attacks was
not considered ethical.
Methods
Study Design and Setting
Laryngeal attacks were evaluated in this prospective, open-
label, uncontrolled extension study (I.M.P.A.C.T.2) in
patients who had participated in the preceding I.M.P.A.C.
T.1 study [15] at seven centers in North America. The data
were obtained between 31 August 2005 and 24 August
2009.
Patients were treated with C1-INH concentrate (50 U/mL
after reconstitution) at a single intravenous dose of 20 U/kg
body weight (4 mL/min) for each attack evaluated at the
study center, irrespective of the intensity of the attack. After
treatment, patients remained at the study center and were
observed until they reported onset of symptom relief. If a
patient was discharged before complete resolution of an
attack, a diary card was issued for the patient to document
the time of complete resolution as well as any concomitant
medication taken. In addition, the patients documented any
adverse events experienced within 7 to 9 days after
824 J Clin Immunol (2010) 30:823–829treatment of the attack. An HAE attack was only to be
reported as an adverse event if the symptoms of a treated
attack had worsened; new attacks were not to be reported as
adverse events.
The study protocol was approved by the Institutional
Review Board at each participating center or by a central
Institutional Review Board. Written informed consent was
obtained from each patient or, if the patient was a minor,
from a legally acceptable representative. Assents were also
obtained when appropriate. An independent data and safety
monitoring board monitored the safety of the study.
Selection of Participants
Patients were eligible for treatment if they had previously
been enrolled in the I.M.P.A.C.T.1 study, irrespective of
their treatment in the study. The total sample size in this
extension study was therefore limited by the number of
patients who had been screened and found eligible for
participation in I.M.P.A.C.T.1.
Other inclusion criteria included being at least 6 years of
age with laboratory and historically confirmed C1-INH
deficiency (type I or II HAE) and having a documented
history of abdominal or facial attacks. Relevant exclusion
criteria included a history of hypersensitivity to C1-INH
concentrate, acquired angioedema due to C1-INH deficien-
cy, all other types of angioedema not associated with C1-
INH deficiency, use of any C1-INH concentrate within 24 h
before the start of treatment in I.M.P.A.C.T.2, and use of
fresh frozen plasma or native plasma within 7 days before
the start of treatment.
Methods of Measurement
The primary endpoint was the time from start of treatment
to onset of symptom relief, as determined by the patient's
responses to a standard question posed at predetermined
intervals for up to 24 h after the start of treatment. This type
of endpoint has been widely used in the evaluation of HAE
therapies [18–20]. In addition, for the preceding I.M.P.A.C.
T.1 study, we retrospectively validated this primary end-
point by correlation with the course of the associated HAE
symptoms (data on file). Secondary endpoints included
time to complete resolution of all symptoms (patient's
assessment), proportion of patients with at least one attack
with onset of relief exceeding 4 h, and proportion of attacks
with a time to onset of relief exceeding 4 h.
Adverse events and vital signs (systolic and diastolic
blood pressure, pulse rate, respiratory rate, and body
temperature) were recorded at appropriate times through-
out the study. A viral safety assessment was performed
before, and 7 to 9 days (parvovirus B19) or 12 weeks
(human immunodeficiency virus type 1 and 2, and
hepatitis A, B, and C virus) after, treatment of the first
attack in I.M.P.A.C.T.2.
Reflecting clinical practice, there were no restrictions for
the time between the onset of an attack and the start of
treatment, or for the use of prior or concomitant medica-
tions, including rescue medications such as analgesics and
anti-emetics.
Data Analysis
Efficacy analyses were based on the intention-to-treat
principle and included all patients and attacks treated with
C1-INH concentrate. Descriptive statistics were calculated
for all efficacy outcomes on a by-patient and by-attack
basis, and confidence intervals were calculated for the
median time to onset of symptom relief and the median
time to complete resolution of all symptoms. For the by-
patient analyses, the mean times for all attacks in a given
patient were used. Missing values for time to onset of
symptom relief were conservatively imputed as the maxi-
mum time to start of relief for the subject involved or, if no
other time to onset of relief was available for the subject, as
the time to complete resolution of all symptoms.
All patients who had received any treatment with C1-
INH concentrate were included in the safety analysis.
Adverse events were coded according to the Medical
Dictionary for Regulatory Affairs (version 12.0), and
incidence rates were calculated for adverse event preferred
terms. No routine laboratory safety data were collected.
Data for vital signs and viral safety were analyzed
descriptively.
All data were analyzed using SAS version 9.1 (SAS
Institute Inc., Cary, NC, USA).
Results
Characteristics of Patients
Each of the 39 laryngeal attacks occurring in 16 patients
was treated with C1-INH concentrate. The median dose
administered was 20 U/kg (range, 18–20 U/kg). The
number of laryngeal attacks treated per patient ranged
between one and eight, with seven patients treated for more
than one laryngeal attack. A total of 14 patients were
female, and two were male (Table I). The mean age was
32 years. All patients but two had type I HAE. The median
time from the estimated start of the laryngeal HAE attack
until the start of treatment was 2.8 h (range, 1–95 h). Of the
39 laryngeal attacks treated, 11 were mild in intensity, 16
were moderate, and 12 were severe.
Apart from systemic antihistamines, diuretics, and sex
hormones taken by two patients each (one patient took
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recorded at the time of C1-INH treatment was taken by no
more than one patient each.
Efficacy Outcomes
The median time between the start of treatment and the
onset of symptom relief was 0.25 h for the 39 laryngeal
attacks analyzed (Table II). All attacks were treated
successfully. The median time to onset of relief for
individual mean values per patient was 0.44 h. Within 1 h
of the start of treatment, onset of relief had been reported in
at least 95% of all attacks, and the time to onset of relief
was ≤0.75 h in at least 85% of patients (Fig. 1).
The median time from start of treatment to complete
resolution of all symptoms was 8.25 h when analyzed by
attack and 5.87 h when analyzed as the mean value per
patient (Table II). The time to complete resolution of all
HAE symptoms was less than 16 h in 75% of patients and
less than 24 h in 74% of attacks (Fig. 2). The onset of
symptom relief occurred within 4 h after the start of
treatment in all patients; the maximum time between the
start of treatment and the onset of symptom relief was 1.3 h.
The intra-subject variability in the time to onset of
symptom relief for the treatment of successive laryngeal
attacks was low in the seven patients who were treated for
more than one laryngeal attack. The maximum variability
occurred in one subject treated for eight attacks, with the
time to onset of relief ranging from 0.12 to 1.0 h.
Safety and Tolerability
Safety was evaluated in all 16 patients treated with C1-INH
concentrate. There were no deaths. Only 2 of the 16
patients experienced an adverse event. None of the adverse
events led to discontinuation of treatment. One patient
experienced a serious adverse event of HAE, which was not
related to the treatment. The attack resolved without
sequelae after 4.4 h. Contrary to the intended study design,
this new attack was reported by the study center as an
adverse event. The other patient had an adverse event of
influenza-like illness, which was assessed by the investiga-
tor as being possibly related to the treatment. This adverse
event resolved within 1 day without sequelae.
No consistent or clinically relevant changes in vital signs
occurred during the study. None of the subjects tested
positive for markers of human immunodeficiency virus,
hepatitis virus, or parvovirus B19 when tested after the first
administration of C1-INH concentrate.
Discussion
C1-INH concentrate is the recommended first-line treat-
ment for HAE attacks at all body locations [7]. Because
Table I Baseline Characteristics of Patients Treated for Laryngeal
HAE Attacks
Characteristic Intention-to-treat population (N=16)
Sex, n (%)
Female 14 (87.5)
Male 2 (12.5)
Age (years)
Mean (SD) 32.3 (12.49)
Range 13–53
Race, n (%)
Caucasian 14 (87.5)
Black 2 (12.5)
Body mass index (kg/m
2)
Mean (SD) 26.6 (4.12)
Range 22–37
Primary disease (type of HAE), n (%)
Type I 14 (87.5)
Type II 2 (12.5)
HAE hereditary angioedema, N total number of patients with laryngeal
attacks, n number of patients with available data, SD standard
deviation
Statistics Time (h)
Patients
a (N=16) Attacks (N=39)
Time to onset of symptom relief—primary efficacy outcome
Mean (SD) 0.53 (0.323) 0.42 (0.291)
Median (range) 0.44 (0.2–1.3) 0.25 (0.1–1.3)
Two-sided 95% CI for median [0.32; 0.72] [0.25; 0.50]
Time to complete resolution of all symptoms
Mean (SD) 11.41 (13.384) 13.87 (13.624)
Median (range) 5.87 (0.6–48.3) 8.25 (0.6–48.9)
Two-sided 95% CI for median [2.05; 18.26] [4.10; 21.50]
Table II Analysis of Time to
Onset of Symptom Relief and
Time to Complete Resolution of
all Symptoms in the Intention-
to-Treat Population
N number of patients/attacks
with available data, CI confi-
dence interval, SD standard
deviation
aAnalysis of mean time for all
attacks per patient
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cause the medical community generally lacks knowledge
about this rare disorder, it is recommended that patients
have an emergency supply of C1-INH concentrate at home
or with them when they travel. However, C1-INH concen-
trate has yet to be licensed in some countries for the
treatment of HAE attacks. Other treatment options, includ-
ing fresh frozen plasma and/or epsilon-amino-caproic acid,
are variable in their efficacy and can be associated with
significant inherent side effects [21]. Therapeutic options
that are effective for histamine-induced angioedema, such
as corticosteroids and antihistamines, are not effective in
the treatment of HAE attacks [8].
Although there is now more than 20 years of clinical
experience with C1-INH concentrate in the treatment of
acute HAE attacks [2], information on its efficacy in the
emergency treatment of laryngeal edema is limited [16].
Furthermore, almost all of the clinical experience with C1-
INH concentrate has been obtained using fixed dosing with
500 or 1,000 U. Until recently, few data had been published
from randomized, controlled studies to demonstrate the
efficacy of C1-INH concentrate compared to placebo.
Where such studies had been conducted, only low numbers
of patients were analyzed [18, 20]. This deficit was
addressed by the recent I.M.P.A.C.T.1 study, which
demonstrated the statistically significant efficacy of a
weight-based dose of C1-INH concentrate (20 U/kg)
compared to placebo in the treatment of abdominal and
facial HAE attacks in 124 patients [15]. Laryngeal attacks
were not investigated in I.M.P.A.C.T.1 due to ethical
concerns about treating this potentially life-threatening type
of attack with placebo.
Against this background, our current study used an
open-label setting to assess whether the beneficial efficacy
of the 20 U/kg dose of C1-INH concentrate seen in the
placebo-controlled I.M.P.A.C.T.1 study is also applicable to
the treatment of laryngeal attacks. We prospectively
investigated the efficacy of C1-INH concentrate in the
emergency treatment of 39 acute laryngeal attacks in 16
patients with HAE. To our knowledge, this is the largest
number of laryngeal attacks that have been investigated in a
prospective study. The primary efficacy endpoint indicated
that C1-INH concentrate given at a single dose of 20 U/kg
induced a rapid onset of relief from the symptoms of the
laryngeal attacks. The median time to onset of relief
reported by the patients was 15 min, thereby substantially
reducing the risk of asphyxiation. In retrospective reports of
laryngeal attacks treated with the same C1-INH concentrate
at fixed doses of up to 1,000 U, the average time to onset of
symptom relief was 15 to 42 min [5, 16, 22]. Similarly, for
laryngeal attacks treated with a different C1-INH concen-
trate at doses of 25 U/kg or up to 2,000 U, the time to onset
of symptom relief ranged from 20 to 60 min [20, 23].
Untreated laryngeal attacks can progress for 8 to 12 h,
after which the symptoms persist for 12 to 24 h and slowly
subside thereafter, with a mean overall duration of 103 h
having been reported for 342 untreated attacks [5, 24]. In
the one controlled study in which laryngeal attacks were
treated with placebo (four attacks in four patients), the
mean time between treatment and onset of relief was 8.5 h
[20]. The symptoms of laryngeal attacks treated with C1-
INH concentrate in our study started to subside rapidly by 6
to 78 min after treatment and were relatively short in
duration (complete resolution after a mean of 13.9 h after
treatment [median of 8.3 h]). Thus, despite the unavoidable
limitation of our study being uncontrolled, the comparison
with these historical data for untreated or placebo-treated
attacks nevertheless indicate the efficacy of C1-INH at the
recommended dose of 20 U/kg in the treatment of laryngeal
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rebound edema after treatment of laryngeal attacks with C1-
INH concentrate, as indicated by no new attacks having
occurred before complete resolution of the previous attack
[15]. Compared to acute HAE attacks at other body
locations, laryngeal attacks show the most rapid response
to infusion of C1-INH concentrate [22], which was
supported by our results for abdominal, facial, and
peripheral attacks treated with the same weight-based dose
of C1-INH concentrate in the I.M.P.A.C.T.2 study (median
time to onset of symptom relief was 20 min for abdominal
attacks, 28 min for facial attacks, and 31 min for peripheral
attacks) (data on file).
Rare laryngeal attacks are experienced by approximately
50% of HAE patients at least once in their lifetime and
represent a continuous threat to these patients because they
mostly occur spontaneously and without warning [4, 5, 25].
An increased risk of developing laryngeal edema has been
associated with the following factors: age between 11 and
45 years, general anesthesia with intubation, history of
laryngeal edema, dental surgery, and facial edema. Although
the first clinical symptoms of HAE are generally abdominal or
facial attacks, and laryngeal attacks occur later in life [5], the
first clinical symptom of HAE can nevertheless be a life-
threatening laryngeal attack, as demonstrated by the case of a
9-year-old boy who died from a laryngeal attack that was the
first clinical sign of his known C1-INH deficiency [10]. The
rapid onset of relief observed in our study, with all attacks
being treated successfully, provides reassurance that the
recommended dose of 20 U/kg for C1-INH concentrate is a
reliable therapeutic option for the emergency treatment of
laryngeal HAE attacks.
The time period available for the emergency treatment of
laryngeal edema lies between the start of the attack and its
maximum development. This period was an average of 8.3 h
for untreated attacks in 61 HAE patients and was relatively
constant in patients experiencing more than one laryngeal
attack [5]. In our study, C1-INH concentrate was mostly
administered during the critical time before maximum
development of the laryngeal attack, with the infusion being
given a median of 2.8 h after the estimated start of the attack.
None of the patients with acute laryngeal attacks treated with
C1-INH concentrate in our prospective study, or with the
same C1-INH concentrate in the retrospective case-collection
s t u d yo fB o r ke ta l .[ 5], required emergency procedures such
as intubation or tracheotomy, and all patients survived the
potentially life-threatening edema. In contrast, intubation or
tracheotomy was necessary in 10% of the 61 patients who
were not treated with C1-INH concentrate in the case-
collection study and 1 of these patients died of asphyxiation
[5]. Only 1 of the 99 patients experiencing laryngeal HAE
attacks who were treated with a different C1-INH concentrate
had to undergo tracheotomy despite C1-INH therapy [23].
The safety analyses in our study revealed no signals of
concern, concurring with the excellent safety profile of C1-
INH concentrate that has been reported in numerous studies
[2, 15, 17, 22, 26, 27]. One concern with the use of plasma-
derived products such as C1-INH concentrate is the
potential risk for virus transmission to recipients. The
manufacture of the highly purified C1-INH concentrate
used in our study includes various measures to ensure
effective virus and prion reduction, resulting in a high
safety margin for this product [28, 29]. During our study,
there was no evidence that the C1-INH treatment was
associated with infections of human immunodeficiency
virus, hepatitis virus, or parvovirus B19, adding to the
experience with more than 400,000 treatments to date with
Berinert in patients experiencing acute HAE attacks during
which no detectable viral transmission occurred.
Conclusions
Our results indicate that C1-INH concentrate at the
recommended weight-based dose of 20 U/kg [15]i sa
highly effective and safe emergency treatment for poten-
tially life-threatening laryngeal attacks in patients with
HAE by providing rapid symptom relief in all treated
patients. Persistence of efficacy with repeated administra-
tion was demonstrated because our study as a whole
assessed the use of C1-INH concentrate in the treatment
of successive HAE attacks (also for attacks at other body
locations). Thus, our findings provide reassurance that C1-
INH concentrate administered at a dose of 20 U/kg is a
reliable, long-term option for the emergency treatment of
laryngeal attacks, reducing the risk of asphyxiation should
this rare type of HAE attack occur.
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